dc.contributor
Institut Català de la Salut
dc.contributor
[Vahdat LT] Weill Cornell Medicine, New York, NY, USA. [Schmid P] Center for Experimental Cancer Medicine, Barts Cancer Institute, London, UK. [Forero-Torres A] University of Alabama School of Medicine, Birmingham, AL, USA. [Blackwell K] Duke University Medical Center, Durham, NC, USA. [Telli ML] Stanford University School of Medicine, Stanford, CA, USA. [Melisko M] University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Vahdat, Linda T.
dc.contributor.author
Forero-Torres, Andres
dc.contributor.author
Blackwell, Kimberly
dc.contributor.author
Telli, Melinda L.
dc.contributor.author
Melisko, Michelle
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Schmid, Peter
dc.date.accessioned
2025-10-25T05:39:27Z
dc.date.available
2025-10-25T05:39:27Z
dc.date.issued
2022-02-22T11:26:34Z
dc.date.issued
2022-02-22T11:26:34Z
dc.date.issued
2021-05-20
dc.identifier
Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study. NPJ Breast Cancer. 2021 May 20;7:57.
dc.identifier
https://hdl.handle.net/11351/7063
dc.identifier
10.1038/s41523-021-00244-6
dc.identifier
000657821100002
dc.identifier.uri
http://hdl.handle.net/11351/7063
dc.description.abstract
Breast cancer; Cancer
dc.description.abstract
Càncer de mama; Càncer
dc.description.abstract
Cáncer de mama; Cáncer
dc.description.abstract
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.
dc.description.abstract
Funding provided by Celldex Therapeutics, Inc.
dc.format
application/pdf
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Nature Research
dc.relation
NPJ Breast Cancer;7
dc.relation
https://doi.org/10.1038/s41523-021-00244-6
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
